Autolus Therapeutics Ltd – ADR (NASDAQ:AUTL) had its Buy rating reiterated by William Blair

Analyst Ratings For Autolus Therapeutics Ltd – ADR (NASDAQ:AUTL)

Story continues below

Today, William Blair reiterated its Buy rating on Autolus Therapeutics Ltd – ADR (NASDAQ:AUTL).

There are 4 Buy Ratings, 1 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.

The current consensus rating on Autolus Therapeutics Ltd – ADR (NASDAQ:AUTL) is Buy with a consensus target price of $44.00 per share, a potential 47.55% upside.

Some recent analyst ratings include

  • 4/3/2019-Autolus Therapeutics Ltd – ADR (NASDAQ:AUTL) had its Buy rating reiterated by William Blair
  • 11/29/2018-Autolus Therapeutics Ltd – ADR (NASDAQ:AUTL) had its Buy rating reiterated by Wells Fargo & Co with a $50.00 price target
  • 7/26/2018-Autolus Therapeutics Ltd – ADR (NASDAQ:AUTL) has coverage initiated with a Neutral rating
  • 7/17/2018-Autolus Therapeutics Ltd – ADR (NASDAQ:AUTL) has coverage initiated with a Buy rating and $37.00 price target

    Recent Trading Activity for Autolus Therapeutics Ltd – ADR (NASDAQ:AUTL)
    Shares of Autolus Therapeutics Ltd – ADR closed the previous trading session at 29,82 −0,48 1,58 % with 23100 shares trading hands.

    An ad to help with our costs